ID Biomedical StreptAvax
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Group A streptococcus vaccine was reported to be safe and well tolerated in 10 adult volunteers at a 50 mcg dose, and "all subjects developed antibody responses to the vaccine," the company said. The trial will continue with ten volunteers tested at each of three doses: 50, 100, and 200 mcg. The study is sponsored and funded by the National Institute of Allergy and Infectious Diseases. The company describes the injectable vaccine as "made from the terminal fragments of the surface M protein," and "designed to produce a preventative immune response against six different strains of group A streptococcus.